

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7275033

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
AMERICAN MONEY MANAGEMENT CORPORATION	04/01/2022

RECEIVING PARTY DATA

Name:	KNOPP BIOSCIENCES LLC
Street Address:	2100 WHARTON STREET, SUITE 615
City:	PITTSBURGH
State/Country:	PENNSYLVANIA
Postal Code:	15203

PROPERTY NUMBERS Total: 39

Property Type	Number
Patent Number:	8017598
Patent Number:	8445474
Patent Number:	8518926
Patent Number:	8519148
Patent Number:	10179774
Patent Number:	8524695
Patent Number:	9849116
Patent Number:	9512096
Patent Number:	10208003
Patent Number:	9650376
Patent Number:	10106536
Patent Number:	10526328
Patent Number:	9662313
Patent Number:	9956206
Patent Number:	10285981
Patent Number:	9468630
Patent Number:	10828284
Patent Number:	10383857
Patent Number:	10383856
Application Number:	15923650

PATENT

Property Type	Number
Application Number:	16460473
Application Number:	16950972
Patent Number:	9763918
Patent Number:	10195183
Patent Number:	9642840
Patent Number:	10028940
Patent Number:	10456381
Application Number:	63061226
Application Number:	63136933
Application Number:	63147024
Patent Number:	9481653
Patent Number:	9914708
Patent Number:	10385025
Application Number:	16346292
Patent Number:	10906877
Application Number:	17127231
Application Number:	63135095
Patent Number:	10851067
Application Number:	17077068

CORRESPONDENCE DATA

Fax Number: (202)956-7069

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2029567685

Email: carrierr@sullcrom.com, nguyenb@sullcrom.com

Correspondent Name: RITA M. CARRIER

Address Line 1: 1700 NEW YORK AVENUE, N.W., SUITE 700

Address Line 2: SULLIVAN & CROMWELL LLP

Address Line 4: WASHINGTON, D.C. 20006-5215

ATTORNEY DOCKET NUMBER: 023489.00005 (RMC)

NAME OF SUBMITTER: RITA M. CARRIER

SIGNATURE: /RITA M. CARRIER/

DATE SIGNED: 04/12/2022

Total Attachments: 6

source=Project Rudolph - Release of IP Security Agreement EXECUTED (4887-3146-5243.1)#page1.tif

source=Project Rudolph - Release of IP Security Agreement EXECUTED (4887-3146-5243.1)#page2.tif

source=Project Rudolph - Release of IP Security Agreement EXECUTED (4887-3146-5243.1)#page3.tif

source=Project Rudolph - Release of IP Security Agreement EXECUTED (4887-3146-5243.1)#page4.tif

source=Project Rudolph - Release of IP Security Agreement EXECUTED (4887-3146-5243.1)#page5.tif

TERMINATION AND RELEASE
OF
INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Release"), dated this 1st day of April, 2022, is by American Money Management Corporation, as Agent ("Agent") for the Lenders (as defined in the Credit Agreement referred to below).

A. WHEREAS, pursuant to the Credit Agreement, dated as of April 9, 2021 (as the same may be amended, restated, supplemented and/or modified from time to time, the "Credit Agreement"), by and among Knopp Biosciences LLC, a Delaware limited liability company (the "Grantor"), the Lenders and the Agent, as Agent for the Lenders, the Lenders have severally agreed to make extensions of credit to the Grantor upon the terms and subject to the conditions set forth therein;

B. WHEREAS, Grantor granted Agent a security interest in the IP Collateral (as defined in the Intellectual Property Security Agreement dated as of April 9, 2021, by Grantor in favor of Agent for the benefit of the Lenders (the "IP Security Agreement")), including, without limitation, (i) its patents listed on Schedule 1 attached hereto (collectively the "Patents") and (ii) its trademarks listed on Schedule 2 attached hereto (collectively, the "Trademarks");

C. WHEREAS the Agent recorded its interest in the Patents with the United States Patent and Trademark Office (the "USPTO") on April 12, 2021, in Reel 055889, Frame 0064;

D. WHEREAS, the Agent recorded its interest in the Trademarks with the USPTO on April 12, 2021, in Reel 7252, Frame 0661; and

E. WHEREAS Grantor requests that the Agent release any and all right, title, and interest in and to the IP Collateral, including, without limitation, the Patents and the Trademarks, and the Agent agrees to release any and all such right, title, and interest.

NOW, THEREFORE, FOR VALUE RECEIVED, the Agent agrees as follows:

1) The Agent does hereby irrevocably terminate and release the IP Security Agreement and its security interest in and to the IP Collateral, including, without limitation, the Patents and the Trademarks and all rights therein of any type or description.

2) The Agent hereby authorizes Grantor (or its authorized representative) to file copies of this Release with the USPTO, and any other document with any other filing office necessary to memorialize this Release and to extinguish the Agent's rights and interest in the IP Collateral, including, without limitation, the Patents and the Trademarks.

3) This Release is governed by the internal laws of the State of New York.

4) This Release shall be binding upon the Agent and its successors and assigns and inures to the benefit of Grantor and its successors and assigns.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed, by an authorized agent, as of the date set forth above.

AMERICAN MONEY MANAGEMENT
CORPORATION

By: 

Name: John S. Ronduti

Title: Senior Vice President

SCHEDULE 1

PATENTS

Owned Patent Portfolio

Ref. No.	Country	Application/ Patent No.	Filing Date	Title
TPHS 401	U.S.	8,017,598 (11/749,497)	05/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same
TPHS 411	U.S.	8,445,474 (13/204,351)	08/05/2011	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same
TPHS 701	U.S.	8,518,926 (11/957,157)	12/14/2007	Compositions and Methods of Using (R)-Pramipexole
TPHS 501	U.S.	8,519,148 (12/049,235)	03/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines
TPHS 521	U.S.	10,179,774 (15/369,230)	12/05/2016	Synthesis of Chirally Purified Substituted Benzothiazole Diamines
TPHS 901	U.S.	8,524,695 (12/048,890)	03/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same
TPHS 1011	U.S.	9,849,116 (14/878,581)	10/08/2015	Compositions and Methods of Using (R)-Pramipexole
TPHS 2301	U.S.	9,512,096 (14/366,590)	06/18/2014	Improved Synthesis of Amine Substituted 4,5,6,7-Tetrahydrobenzothiazole Compounds
TPHS 2311	U.S.	10,208,003 (15/332,599)	10/24/2016	Improved Synthesis of Amine Substituted 4,5,6,7-Tetrahydrobenzothiazole Compounds
TPHS 2701	U.S.	9,650,376 (14/776,271)	09/14/2015	Imidazo[4,5-B]pyridin-2-yl amides as KV7 Channel Activators
TPHS 2711	U.S.	10,106,536 (15/591,884)	05/10/2017	Imidazo[4,5-B]pyridin-2-yl amides as KV7 Channel Activators
TPHS 2721	U.S.	10,526,328 (16/124,853)	09/07/2018	Imidazo[4,5-B]pyridin-2-yl amides as KV7 Channel Activators
TPHS 3001	U.S.	9,662,313 (14/194,558)	02/28/2014	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders
TPHS 3011	U.S.	9,956,206 (15/492,832)	04/20/2017	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders
TPHS 3021	U.S.	10,285,981 (15/926,812)	03/20/2018	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders
TPHS 3501	U.S.	9,468,630 (13/966,229)	08/13/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils
TPHS 3521	U.S.	10,828,284 (14/904,058)	01/08/2016	Compositions and Methods for Treating Conditions Related to Increase Eosinophils
TPHS 3531	U.S.	10,383,857 (15/889,714)	02/06/2018	Compositions and Methods for Treating Conditions Related to Increase Eosinophils
TPHS 3541	U.S.	10,383,856 (15/181,526)	06/14/2016	Compositions and Methods for Treating Conditions Related to Increase Eosinophils
TPHS 3551	U.S.	15/923,650	03/16/2018	Compositions and Methods for Treating Conditions Related to Increase Eosinophils

Ref. No.	Country	Application/ Patent No.	Filing Date	Title
TPHS 3561	U.S.	16/460,473	07/02/2019	Compositions and Methods for Treating Conditions Related to Increase Eosinophils
TPHS 3591	U.S.	16/950,972	11/18/2020	Compositions and Methods for Treating Conditions Related to Increase Eosinophils
TPHS 3701	U.S.	9,763,918 (14/912,015)	02/12/2016	Compositions and methods for treating chronic idiopathic urticaria
TPHS 3711	U.S.	10,195,183 (15/675,912)	08/14/2017	Compositions and methods for treating chronic idiopathic urticaria
TPHS3801	U.S.	9,642,840 (14/912,058)	08/15/2013	Compositions and methods for treating multiple myeloma
TPHS3811	U.S.	10,028,940 (15/461,131)	03/16/2017	Compositions and methods for treating multiple myeloma
TPHS 3821	U.S.	10,456,381 (16/013,071)	06/20/2018	Compositions and methods for treating multiple myeloma
TPHS 5100	U.S.	63/061,226	08/05/2020	Use of Dexpramipexole for the Treatment of Asthma
TPHS 5110	U.S.	63/136,933	01/13/2021	Use of Dexpramipexole for the Treatment of Asthma
TPHS 5120	U.S.	63/147,024	02/08/2021	Use of Dexpramipexole for the Treatment of Asthma
TPHS 4101	U.S.	9,481,653 (14/853,815)	09/14/2015	Benzoimidazol-1,2-yl amides as Kv7 Channel Activators
TPHS 4111	U.S.	9,914,708 (15/339,590)	10/31/2016	Benzoimidazol-1,2-yl amides as Kv7 Channel Activators
TPHS 4121	U.S.	10,385,025 (15/879,792)	01/25/2018	Benzoimidazol-1,2-yl amides as Kv7 Channel Activators
TPHS 4131	U.S.	16,346,292	04/30/2019	Benzoimidazol-1,2-yl amides as Kv7 Channel Activators
TPHS 4141	U.S.	10,906,877 (16/460,449)	07/02/2019	Benzoimidazol-1,2-yl amides as Kv7 Channel Activators
TPHS 4151	U.S.	17/127,231	12/18/2020	Benzoimidazol-1,2-yl amides as Kv7 Channel Activators
TPHS 4350	U.S.	63/135,095	01/08/2021	Pyrazolo[1,5-A]pyridin-2,3-yl amides as Kv7 Channel Activators
TPHS 4601	U.S.	10,851,067 (16/358,642)	03/19/2019	Kv7 Channel Activators Compositions and Methods of Use
TPHS 4611	U.S.	17/077,068	10/22/2020	Kv7 Channel Activators Compositions and Methods of Use

Licensed Patent Portfolio

Ref. No.	Country	Application/ Patent No.	Filing Date	Title
TPHS 1701	U.S.	7,157,480 (10/496,714)	05/26/2004	Use of Pramipexole to Treat Amyotrophic Lateral Sclerosis

SCHEDULE 2

TRADEMARKS

Mark	Country	Registration/ Application Number
Knopp	U.S.	4,092,643
Knopp Logo	U.S.	4,094,876
Knopp Biosciences	U.S.	4,092,645